Eltrombopag

Drug Profile

Eltrombopag

Alternative Names: 497115; Eltrombopag olamine; Promacta; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer GlaxoSmithKline; Novartis; Technische Universitat Dresden
  • Class Benzoates; Hydrazines; Pyrazoles; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 10 Apr 2017 Novartis plans regulatory submissions for eltrombopag for Aplastic anaemia (First-line therapy) in 2017
  • 25 Jan 2017 Novartis completes a phase II trial in Thrombocytopenia (chemotherapy-induced) in Australia, Belgium, Canada, Greece, Hungary, Israel, Russia, South Korea, Poland and USA (NCT01890746)
  • 16 Jan 2017 Novartis Pharmaceuticals plans a phase II trial for Aplastic anaemia (Combination therapy, In infants, In children, In adolescents) in USA (PO) (NCT03025698)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top